Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.3
(13.46%)
HKD 0.3
(13.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.34 Billion CNY | -0.48% |
| 2022 | 1.35 Billion CNY | 8.95% |
| 2021 | 1.23 Billion CNY | -0.16% |
| 2020 | 1.24 Billion CNY | 5.54% |
| 2019 | 1.17 Billion CNY | 1.11% |
| 2018 | 1.16 Billion CNY | 22.29% |
| 2017 | 951.22 Million CNY | -17.36% |
| 2016 | 1.15 Billion CNY | -15.45% |
| 2015 | 1.36 Billion CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.33 Billion CNY | 0.0% |
| 2024 Q1 | 1.33 Billion CNY | -0.47% |
| 2023 Q1 | 1.31 Billion CNY | -2.8% |
| 2023 FY | 1.34 Billion CNY | -0.48% |
| 2023 Q4 | 1.34 Billion CNY | 0.0% |
| 2023 Q3 | 1.34 Billion CNY | 2.39% |
| 2023 Q2 | 1.31 Billion CNY | 0.0% |
| 2022 Q3 | 1.35 Billion CNY | 10.77% |
| 2022 FY | 1.35 Billion CNY | 8.95% |
| 2022 Q2 | 1.21 Billion CNY | 0.0% |
| 2022 Q1 | 1.21 Billion CNY | -1.64% |
| 2022 Q4 | 1.35 Billion CNY | 0.0% |
| 2021 Q1 | 1.28 Billion CNY | 3.5% |
| 2021 Q3 | 1.23 Billion CNY | -3.54% |
| 2021 Q4 | 1.23 Billion CNY | 0.0% |
| 2021 FY | 1.23 Billion CNY | -0.16% |
| 2021 Q2 | 1.28 Billion CNY | 0.0% |
| 2020 Q1 | 1.22 Billion CNY | 3.95% |
| 2020 FY | 1.24 Billion CNY | 5.54% |
| 2020 Q4 | 1.24 Billion CNY | 0.0% |
| 2020 Q3 | 1.24 Billion CNY | 1.52% |
| 2020 Q2 | 1.22 Billion CNY | 0.0% |
| 2019 Q3 | 1.17 Billion CNY | 7.01% |
| 2019 Q1 | 1.09 Billion CNY | -5.51% |
| 2019 Q2 | 1.09 Billion CNY | 0.0% |
| 2019 FY | 1.17 Billion CNY | 1.11% |
| 2019 Q4 | 1.17 Billion CNY | 0.0% |
| 2018 Q2 | 873.15 Million CNY | 0.0% |
| 2018 Q4 | 1.16 Billion CNY | 0.0% |
| 2018 Q3 | 1.16 Billion CNY | 33.22% |
| 2018 FY | 1.16 Billion CNY | 22.29% |
| 2018 Q1 | 873.15 Million CNY | -8.21% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q4 | 951.22 Million CNY | 0.0% |
| 2017 FY | 951.22 Million CNY | -17.36% |
| 2016 Q4 | 1.15 Billion CNY | 0.0% |
| 2016 FY | 1.15 Billion CNY | -15.45% |
| 2015 FY | 1.36 Billion CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -48.077% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 94.032% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -4.394% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | 35.863% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -181.049% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 53.514% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | 52.477% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | 22.207% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -59.218% |
| SSY Group Limited | 11.96 Billion HKD | 88.771% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | 3.237% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 61.463% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 99.505% |